Dan Sunnemark

Soedertaelje, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: June 30, 2025

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: June 30, 2025

Development and In Vitro Characterization of [3H]GMC-058 as Radioligand for Imaging Parkinsonian-Related Proteinopathies.

Development and In Vitro Characterization of [3H]GMC-058 as Radioligand for Imaging Parkinsonian-Related Proteinopathies.

Journal: Cells

Published: April 04, 2025

Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand.

Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand.

Journal: ACS chemical neuroscience

Published: November 11, 2024

[11 C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome.

[11 C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome.

Journal: Synapse (New York, N.Y.)

Published: December 28, 2022

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.

Journal: Molecular and cellular neurosciences

Published: March 02, 2021

Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein.

Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein.

Journal: Brain research

Published: April 29, 2020

Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease.

Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease.

Journal: Cell and tissue research

Published: September 09, 2016

Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.

Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 08, 2014

MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.

MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.

Journal: Acta neuropathologica communications

Published: December 05, 2013

Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.

Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.

Journal: Neuromolecular medicine

Published: December 29, 2012

Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.

Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.

Journal: Journal of Alzheimer's disease : JAD

Published: September 25, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026